Sofgen Pharma S.A. (PROCF)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2022	FY 2020	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Jan 1, 2022	Dec 31, 2020	Jan 1, 2020
CAN	58.56M	75.66M	77.31M	64.20M	44.81M
CAN Growth	-22.61%	-2.13%	20.42%	43.27%	-17.98%
Procaps Colombia	139.52M	148.27M	145.28M	156.85M	121.53M
Procaps Colombia Growth	-5.90%	2.06%	-7.38%	29.06%	-2.06%
CASAND	65.91M	96.32M	80.04M	67.61M	40.09M
CASAND Growth	-31.58%	20.34%	18.40%	68.62%	-5.29%
Diabetrics	44.57M	40.10M	34.47M	47.62M	39.22M
Diabetrics Growth	11.13%	16.35%	-27.63%	21.42%	6.20%
Nextgel	221.71M	243.04M	253.47M	241.56M	201.29M
Nextgel Growth	-8.78%	-4.12%	4.93%	20.01%	4.71%
Intra-Segment Eliminations	-156.46M	-179.65M	-187.35M	-174.10M	-117.91M
Corporate	-	-	-	-	2.43M
Corporate Growth	-	-	-	-	-79.11%
Total	373.80M	423.75M	403.20M	403.74M	331.47M
Total Growth	-11.79%	5.10%	-0.13%	21.80%	2.06%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2022	FY 2020	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Jan 1, 2022	Dec 31, 2020	Jan 1, 2020
South America	256.76M	293.46M	275.77M	280.70M	249.98M
South America Growth	-12.50%	6.42%	-1.76%	12.29%	3.45%
Central America	57.88M	83.49M	83.01M	68.19M	58.08M
Central America Growth	-30.68%	0.59%	21.72%	17.41%	-8.98%
North America	49.85M	39.03M	34.24M	46.33M	12.58M
North America Growth	27.74%	13.99%	-26.10%	268.40%	-17.27%
Europe	9.31M	7.77M	10.19M	8.52M	10.83M
Europe Growth	19.77%	-23.76%	19.69%	-21.34%	162.51%
Total	373.80M	423.75M	403.20M	403.74M	331.47M
Total Growth	-11.79%	5.10%	-0.13%	21.80%	2.06%

Source: S&P Global Market Intelligence.